| 000 | 01755 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518061154.0 | ||
| 264 | 0 | _c20200601 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1460-2083 | ||
| 024 | 7 |
_a10.1093/hmg/ddz218 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuang, Hsiang-Po | |
| 245 | 0 | 0 |
_aUsing human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential. _h[electronic resource] |
| 260 |
_bHuman molecular genetics _c12 2019 |
||
| 300 |
_a3880-3894 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAzoles _xadministration & dosage |
| 650 | 0 | 4 | _aBlood-Brain Barrier |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 | _aCell Culture Techniques |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycogen Storage Disease Type II _xdrug therapy |
| 650 | 0 | 4 |
_aGonanes _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInduced Pluripotent Stem Cells _xcytology |
| 650 | 0 | 4 | _aInjections, Intraperitoneal |
| 650 | 0 | 4 | _aIsoindoles |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeural Stem Cells _xcytology |
| 650 | 0 | 4 |
_aOrganoselenium Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aWortmannin _xpharmacology |
| 650 | 0 | 4 |
_aalpha-Glucosidases _xgenetics |
| 700 | 1 | _aChiang, Wei | |
| 700 | 1 | _aStone, Lee | |
| 700 | 1 | _aKang, Chun-Kai | |
| 700 | 1 | _aChuang, Ching-Yu | |
| 700 | 1 | _aKuo, Hung-Chih | |
| 773 | 0 |
_tHuman molecular genetics _gvol. 28 _gno. 23 _gp. 3880-3894 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/hmg/ddz218 _zAvailable from publisher's website |
| 999 |
_c30109417 _d30109417 |
||